

## TARGET MARKET DETERMINATION

**Made by:** InhaleRX Limited ACN 611 845 820 (the **Company**)

**Effective Date:** 26 November 2025

**Product:** Free-attaching options to acquire fully paid ordinary shares in the Company (**Shares**) to be issued in connection with an entitlement offer (**Entitlement Offer**)

### 1 IMPORTANT INFORMATION ABOUT THIS DOCUMENT

---

This target market determination (**TMD**) has been prepared by the Company in relation to an offer of up to 4,953,367 options over Shares (exercisable at \$0.042) and expiring on 22 December 2027 to eligible shareholders who participated in the Entitlement Offer (**Options**) under the Company's prospectus dated 26 November 2025 (**Prospectus**) (available to view at <https://inhalerx.com.au/company-announcements/>).

Capitalised terms used but not defined in this TMD have the meaning ascribed to them in the Prospectus.

Under the Prospectus, eligible shareholders who apply for Shares in the Entitlement Offer under the Prospectus (and an associated shortfall offer) will receive one Option for every two Shares subscribed for under the Entitlement Offer (and shortfall offer) (**Offer**).

This TMD sets out the class of consumers for whom the Options would likely be consistent with their financial objectives, the distribution conditions and restrictions and restrictions imposed on the distribution of the Options and reporting requirements for distributors in accordance with the requirements of section 994B of the *Corporations Act 2001* (Cth) (**Corporations Act**).

Any recipient of this TMD should carefully read and consider the Prospectus in full and consult their stockbroker, accountant or other professional advisor if they have any questions regarding the contents of the Prospectus. Any recipient of this TMD who wants to acquire Options under the Offer will need to subscribe for new Shares under the Entitlement Offer and complete the relevant Application Form accompanying the Prospectus. There is no cooling-off period in respect of the issue of the Options. This TMD is not a disclosure document for the purposes of the Corporations Act and, therefore, has not been lodged and does not require lodgement with the Australian Securities and Investments Commission (**ASIC**).

This TMD does not consider your personal financial circumstances. It is essential for you to consider these matters and carefully read the Prospectus before making an investment decision. The Company is not licenced to provide financial product advice in relation to the Options.

## 2 TARGET MARKET

The table below summarises the overall class of consumers that fall within the target market for Options based on the product's key attributes, financial situation, and needs, which it has been designed to meet.

TMD Requirement	Target Market Determination
Investment Objective	The Company expects that an investment in the Options will be suitable for investors seeking the right, but not the obligation, to gain exposure to an Australian biotechnology company specialising in precision medicine delivered through inhalation.
Investment Timeframe	<p>The target market of investors will take a medium to long-term outlook in relation to their investment.</p> <p>Option holders will also be able to exercise Options and trade the underlying Shares issued on exercise (irrespective of whether the Options are quoted on the ASX). However, investors should be aware that such dealing is only likely to be commercially viable if the Shares' trading price exceeds the Options' exercise price both at the date of exercise and at the date of sale.</p> <p>Investors with a medium—to long-term outlook will benefit from the ability to exercise Options within the exercise period and increase their shareholding and exposure to the Shares in the future.</p> <p>Given the need to pay the exercise price to acquire the underlying Shares, investors in the target market are those in a financial position sufficient for them to accept the Options now with a 24-month time horizon before they lapse. During this time, their ability to liquidate their Options by way of exercise may be limited by the trading price of the underlying Shares.</p>
Investment Metrics	While the Company does not have an established eligibility framework for investors based on metrics such as age, expected return or volatility, the target market of investors will likely be able to withstand potential fluctuations and potential losses in the value of their investors. The Options do not offer guaranteed income or capital protection.
Risks	The Company considers that, while the issue price of the Options is free, an

	<p>investment in the Company offered in connection with the Prospectus should be regarded as high risk since there is no guarantee that the Company's share price will ever exceed the exercise price of the Options. The Options may ultimately prove to be worthless. Investors should consider this when subscribing for new Shares under the Entitlement Offer and taking up their right to the free attaching Options. The Options are not regarded as appropriate for an investor who could not bear a loss of some or all of the investment.</p> <p>Investors should also have sufficient financial literacy and resources (either alone or in conjunction with an appropriate adviser) to understand and appreciate the risks of investing in the Options as an asset class generally and the more specific risks of investing in the Company.</p> <p>Section 6 of the Prospectus sets out specific risks relating to the Company and an investment in the Shares and Options, and investors should review those risks carefully before deciding whether to invest.</p>
--	---

### 3 DISTRIBUTION CONDITIONS

---

The Options are only available to Eligible Shareholders of the Company who participate in the Entitlement Offer.

"Eligible Shareholders" are eligible to participate in the Entitlement Offer and associated shortfall offer if they:

- (a) have a registered address in Australia or New Zealand, and
- (b) were holders of Shares on 1 December 2025.

A copy of the Prospectus and access to this TMD will be made available to all applicants under the Prospectus before they complete an application for new Shares, which automatically incorporates an application for Options.

The Company considers that these distribution conditions will ensure that persons who receive Options will fall within the target market in circumstances where personal advice is not being provided to those persons by the Company.

### 4 REVIEW TRIGGERS

---

The Options are being offered for a limited offer period set out in the Prospectus, after the conclusion of which the Options will no longer be available for investment by way of issue. It follows that the TMD will only apply between the commencement of the offer of the Options under the Prospectus and the issue of the Options shortly after the close of the Entitlement Offer (**Offer Period**), during which the TMD will be withdrawn.

To allow the Company to determine whether circumstances exist that indicate this TMD is no longer appropriate to the Options and should be reviewed the following review triggers apply for the Offer Period:

- (a) there is a material change to the Option's key attributes that makes it no longer consistent with the likely objectives, financial situation and needs of clients in the target market;
- (b) the Company lodges with ASIC a supplementary or replacement prospectus in relation to the Prospectus;
- (c) the occurrence of a significant dealing in Options inconsistent with this TMD. The Company does not consider that an on-sale of the Options on market is a significant dealing;
- (d) the Company identifies a substantial divergence in how the Options are being distributed and purchased from this TMD;
- (e) ASIC raises concerns with the Company regarding the adequacy of the design or distribution of the Options or this TMD; and
- (f) material changes to the regulatory environment that applies to an investment in the Options.

The Company may also update or amend this TMD at any time.

## 5 REVIEW PERIOD

If a review trigger occurs during the Offer Period, the Company will undertake a review of the TMD in light of the review trigger as soon as reasonably practicable.

The Company will otherwise complete a review of the TMD immediately before the issue of Options under the Offers. Given the short length of the Offer Period, the Company does not intend to undertake period reviews of this TMD.

## 6 INFORMATION REPORTING

Reporting requirement	Period for reporting to the Company by the distributor	Information to be provided
Whether the distributor received complaints about the Options	<ul style="list-style-type: none"> <li>• For the duration of the offers, remain open within ten business days after the end of each quarter.</li> <li>• Within ten business days after the end of the Offer Period.</li> </ul>	<ul style="list-style-type: none"> <li>• The number of complaints received.</li> <li>• A summary of the nature of each complaint or a copy of each complaint.</li> </ul>
A significant dealing of the Options that is not consistent with this	It should be as soon as reasonably practicable after the significant dealing occurs, but in any event, no later than ten business days after the significant dealing occurs.	<ul style="list-style-type: none"> <li>• Details of the significant dealing.</li> <li>• Reasons why the distributor considers the significant dealing inconsistent with this TMD.</li> </ul>

A summary of the steps taken by the distributor to ensure that its conduct was consistent with this TMD	Within ten business days after the close of the Offer Period of Options in accordance with the Prospectus.	A summary of the steps taken by the distributor to ensure that its conduct was consistent with this TMD.
---	--	--

## **7 CONTACT DETAILS**

---

Contact details in respect of this TMD for the Company are:

James Barrie  
Company Secretary  
Phone: +61 3 9070 1221  
Email: [info@inhalerx.com.au](mailto:info@inhalerx.com.au)